Professional Documents
Culture Documents
126 mg/dL
IR
OAD
.SU
(OHA)
(OAD)
.SU
.
(AHA)
KATP
[ATP]
[ADP]
Ca2+
-40 mV
Ca2+
KATP
Ca2+
-40 mV
Ca2+
SUR1
SUR2A
SUR2B
Kir6.2
Basal state of
KATP channel
Pancreatic Open
Cardiac
muscle
Closed
Stimulus
Effect
Glucose
closes
Ischemia
and hypoxia
open
Insulin
secretion
1. Reduce energy
consumption
2. Increase
arrhythmias
3. Ischemic
preconditioning
Vascular
smooth
muscle
Closed
Ischemia
and hypoxia
open
Vasodilatation
KATP
(on SUR) IC50
SUR1
SUR2A
50 nM
10 M
260 nM
3 nM
3 nM
98nM
480 nM
27 nM
3 nM
HbA1c (%)
20
10
0
-.25
-.5
-.75
-1
-1.25
-1.5
-1.75
-2
500mg
(n=73)
1,000mg
(n=73)
1,500mg 2,000mg
(n=76) (n=73)
500~2000mg
--
2000mg
HbA1c 2%
Garber AJ, Duncan TG, Goodman AM, et al,
Am J Med 1997; 103(6): 491-497
-
-
- , 0.03/
-
-
-
(Acarbose)(Miglitol)
(Voglibose)(Emiglitate)
In
50mg
100mg
50mg tid
800
700
600
500
400
300
(pmol200
/min)100
6am
(n=14)
2
(n=16)
10am
2pm
6pm
10pm
2am
6am
8%92%
-
Troglitazone
Rosiglitazone
Pioglitazone
Troglitazone
PPAR
4~5%
Hb
Starlings2
100
OGTT
(mU/l)
80
60
40
20
0
(mg/dl)
80
120
160
200
90
BMI18.5-23kg/m2
BMI2325kg/m2
BMI>25
>90cm()
>80cm()
BMI18.5-25kg/m2
BMI2530kg/m2
BMI>30
>102cm()
>88cm()
*National Heart, Lung and Blood Institute(NHLB) of NIH published clinical guidelines
on identification,evaluation and treatment of overweight and obesity in adults, 1998
(/)(//)
2
(mmol/L)
4.46.1
4.48.0
7.0
10.0
>7.0
>10.0
<6.5
HbA1c(%)
<130/80
(mmHg)
BMI(kg/m2)
<25
<24
6.57.5
>130/80
<140/90
<27
<26
>7.5
140/90
27
26
TC(mmol/L)
<4.5
4.5
HDL-C(mmol/L)
>1.1
1.10.9
<0.9
TG(mmol/L)
<1.5
<2.2
2.2
LDL-C(calculated)
<3.0
2.54.0
>4.0
6.0